Key takeaways
- Eli Lilly's experimental triple-agonist retatrutide resolved obstructive sleep apnea in up to 73% of patients in two Phase III TRIUMPH trials.
- The drug reduced apnea-hypopnea index (AHI) by up to 24.4 events per hour in patients without diabetes and up to 15.1 events per hour in those with diabetes.
- Participants achieved significant mean body weight reductions of up to 22.2% over the course of the 80-week study period.
- These clinical outcomes are comparable to those of tirzepatide (Zepbound), offering a potent next-generation alternative for patients.
What happened
In late October 2026, clinical researchers presented landmark Phase III data demonstrating that Eli Lilly’s experimental triple-agonist drug, retatrutide, successfully resolved obstructive sleep apnea (OSA) in up to 73% of patients. The findings, published in the New England Journal of Medicine and presented at the Congress of the European Sleep Research Society, come from the parallel TRIUMPH-1-OSA and TRIUMPH-2-OSA trials. This marks the first dedicated sleep apnea clinical data released for Lilly’s highly anticipated "triple G" successor to tirzepatide.
Why it matters
Obstructive sleep apnea affects millions of Americans with obesity, but traditional treatments like Continuous Positive Airway Pressure (CPAP) machines suffer from poor patient compliance. By demonstrating that retatrutide can reverse sleep apnea severity to the point of clinical remission, these trials position the drug as a powerful therapeutic alternative.
For cash-pay consumers and telehealth patients, these findings are highly significant. Broad clinical data linking weight-loss medications to the resolution of co-morbidities like OSA is the primary driver behind expanding US health insurance coverage. Proving that next-generation molecules can cure sleep apnea makes it far more likely that commercial insurance and employer plans will cover these high-cost therapies in the future, reducing the reliance on out-of-pocket cash pay.
What the data says
The two international Phase III trials evaluated weekly subcutaneous injections of retatrutide at doses of 4 mg, 9 mg, and 12 mg against a placebo over 80 weeks. The trials featured distinct patient profiles:
- TRIUMPH-1-OSA: Evaluated 243 overweight or obese adults with moderate-to-severe sleep apnea who did not have type 2 diabetes.
- TRIUMPH-2-OSA: Evaluated 448 overweight or obese adults with moderate-to-severe sleep apnea who also had type 2 diabetes.
To measure sleep apnea severity, researchers tracked the Apnea-Hypopnea Index (AHI), which measures the number of times a person stops breathing per hour of sleep. The clinical findings showed:
- Sleep Apnea Reduction: In patients without diabetes, the 9 mg and 12 mg doses of retatrutide cut AHI by 24.4 and 21.9 more events per hour than the placebo. In patients with type 2 diabetes, those doses reduced AHI by 14.4 and 15.1 more events per hour than the placebo.
- Disease Remission: Clinical remission (defined as bringing AHI below 5 events per hour, or to 5–14 events per hour with minimal daytime sleepiness) was achieved by up to 73% of patients in the highest-dose cohorts across the trials, compared to roughly 12% in the placebo groups.
- Weight Loss: Patients without diabetes achieved a mean body weight loss of 12.5% to 22.2% on retatrutide, while those with type 2 diabetes lost between 12.1% and 18.5% of their body weight.
How it compares
Retatrutide is a "triple agonist" targeting three hunger-related hormone receptors: GIP, GLP-1, and glucagon. Current-generation options like semaglutide (Wegovy) target only GLP-1, while tirzepatide (Zepbound) targets both GLP-1 and GIP.
In clinical terms, medical experts noted that retatrutide’s sleep apnea resolution closely mirrors the results of tirzepatide. In the SURMOUNT-OSA trials, tirzepatide reduced AHI by 20 to 23.8 events per hour. While some endocrinologists expected the triple-agonist action of retatrutide to vastly outperform tirzepatide, sleep specialists point out that having another highly effective option is invaluable for patients who do not respond to existing first-generation GLP-1 therapies.
For patients evaluating telehealth weight-loss options, comparing these future molecular benchmarks is helpful when looking at current providers on the /providers directory or utilizing the online /compare tool. Currently, brand-name Zepbound carries a retail price of over $1,000 per month without insurance, though telehealth cash-pay options for compounded alternatives hover between $250 and $450 per month. Retatrutide is expected to command a premium brand-name price upon FDA approval, but its superior weight-loss profile could shake up the cash-pay landscape.
How this fits the bigger picture
The TRIUMPH-OSA data represents the latest escalation in the next-generation weight-loss pipeline, where Eli Lilly and Novo Nordisk are competing fiercely to establish new clinical benchmarks. This trial represents a major milestone for retatrutide, building directly on earlier Phase III success. We previously analyzed how the drug established its metabolic efficacy in our coverage of Lilly’s retatrutide TRIUMPH-2 diabetes trial, which established an historic 18.8% weight loss benchmark for diabetic patients.
At the same time, Novo Nordisk is developing its own high-potency combination drug, CagriSema. As we reported in our analysis of how Novo CagriSema drives 25% weight loss for women, the industry is rapidly moving past simple GLP-1 single-agonist therapies. For US buyers shopping for telehealth weight-loss options, these developments highlight that the future of obesity medicine lies in multi-receptor targeting. As these next-gen clinical profiles expand to include sleep apnea, heart failure, and metabolic health, the pressure on insurance companies to provide universal coverage will continue to mount.
What happens next
Retatrutide remains an investigational drug and is not yet approved by the US Food and Drug Administration (FDA) for weight loss or sleep apnea. Eli Lilly is continuing to run its extensive TRIUMPH global Phase III clinical program, which is evaluating the drug's safety and efficacy across several primary endpoints.
US buyers can expect complete Phase III trial readouts to continue surfacing through late 2026 and 2027. Once the safety and efficacy database is complete, Lilly will submit retatrutide to the FDA for regulatory approval. Until then, patients seeking medical weight loss can explore existing GLP-1 options by consulting licensed medical professionals and checking their coverage options using our interactive /questionnaire.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare professional before starting any weight-loss or medical treatment program.